Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ALM-223 by Almirall for Systemic Lupus Erythematosus: Likelihood of Approval
ALM-223 is under clinical development by Almirall and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase...